CYP19A1 and breast carcinoma: Treatment of breast cancer patients with the aromatase inhibitor letrozole causes a significant reduction in Treg cells in the TME (p < 0.0001)77 and in ER positive breast cancer patients increases tumor infiltration by B cells and CD4+ T cells.78